UK markets closed

Regen BioPharma, Inc. (RGBP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.7200-0.0200 (-2.70%)
As of 01:17PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.78M
Enterprise value 3.39M
Trailing P/E 31.20
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.79
Price/book (mrq)N/A
Enterprise value/revenue 14.34
Enterprise value/EBITDA -4.12

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-56.47%
S&P500 52-week change 321.08%
52-week high 32.5500
52-week low 30.4010
50-day moving average 30.7598
200-day moving average 31.2283

Share statistics

Avg vol (3-month) 314.51k
Avg vol (10-day) 38.83k
Shares outstanding 53.75M
Implied shares outstanding 63.75M
Float 84.11M
% held by insiders 10.01%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:1500
Last split date 306 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-171.12%

Management effectiveness

Return on assets (ttm)-84.06%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)236.56k
Revenue per share (ttm)0.06
Quarterly revenue growth (yoy)0.00%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-1.03M
Diluted EPS (ttm)-0.2400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)78.11k
Total cash per share (mrq)0.02
Total debt (mrq)693.77k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.02
Book value per share (mrq)-1.26

Cash flow statement

Operating cash flow (ttm)-482.07k
Levered free cash flow (ttm)281.51k